Literature DB >> 10372225

Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol.

K Matsui1, T Kiyosue, J C Wang, K Dohi, M Arita.   

Abstract

In this study, we compared the effects of pimobendan (PIM), a putative Ca(2+)-sensitizer and phosphodiesterase (PDE) inhibitor, on the L-type Ca2+ current (ICa) of guinea-pig ventricular myocytes and contractile tension of ventricular papillary muscles with those of a nonselective PDE inhibitor, isobutylmethylxanthine (IBMX), and selective PDE-III inhibitors, that is, milrinone (MIL) and cilostazol (CIL). The efficacy (maximum attainable effect) of these drugs for increasing ICa or developed tension (DT) ranged in the order of IBMX >> MIL > PIM > CIL. This finding suggests that the positive inotropic effect of each drug is roughly proportional to its increasing effect on ICa. The additional effect of PIM (a Ca(2+)-sensitizing effect) was not identified in "intact" preparations, and the potentiating effects of PIM on the DT and ICa were virtually the same as those observed for MIL. To isolate the Ca(2+)-sensitizing effect of PIM on the DT, we studied the effects of PIM in the presence of H89, an isoquinoline derivative possessing a selective inhibitory effect on cAMP-dependent protein kinase. In the absence of H89, 50 microM PIM increased the DT by 68 +/- 11% (mean +/- SE, n = 6). However, in the presence of 20 microM H89, which completely blocked the PIM-induced increase in ICa, PIM (50 microM) significantly increased the DT by 19 +/- 6% (n = 6), thereby indicating the presence of a positive inotropic effect attributable to a mechanism other than increased intracellular cAMP, that is, a Ca(2+)-sensitizing effect. The latter notion was supported by the finding that in the presence of H89 (20 microM), the PIM-induced augmentation of DT was accompanied by a prolongation of the time to 50% relaxation of contractile tension. In contrast, MIL (50 microM) and forskolin, a direct activator of adenylate cyclase (1-10 nM), did not increase DT in the presence of 20 microM H89. These results suggest that the fraction of positive inotropic effect of PIM attributable to its Ca(2+)-sensitizing effect is masked by its potent PDE-III inhibitory effect in "intact" ventricular preparations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372225     DOI: 10.1023/a:1007779908346

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  9 in total

Review 1.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

Review 2.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2016-07-13       Impact factor: 6.343

Review 3.  J-wave syndromes: Brugada and early repolarization syndromes.

Authors:  Charles Antzelevitch; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2015-04-11       Impact factor: 6.343

Review 4.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

5.  Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome.

Authors:  Tamás Szél; István Koncz; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-08-01       Impact factor: 6.343

Review 6.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

7.  Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.

Authors:  Bence Patocskai; Hector Barajas-Martinez; Dan Hu; Zsolt Gurabi; István Koncz; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2016-01-25       Impact factor: 6.343

8.  Role of pharmacotherapy in Brugada syndrome.

Authors:  Takeshi Tsuchiya
Journal:  Indian Pacing Electrophysiol J       Date:  2004-01-01

9.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  J Arrhythm       Date:  2016-08-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.